|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||25.98 - 26.82|
|52 Week Range||16.56 - 29.44|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||74.10|
|Earnings Date||May 27, 2019 - May 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.56|
Shares of pharmaceutical companies toppled Tuesday on reports the House of Representatives will release a plan that allows the federal government to negotiate drug prices in Medicare.
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
-- If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease --
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharmaceutical stocks slipped a single-digit percentage in the first eight months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.
- Current Executive Vice President and Chief Business Officer, Robert F. Carey, will Retire Effective Oct. 1. -
Chairman, President and CEO of Horizon Therapeutics Plc (30-Year Financial, Insider Trades) Timothy P Walbert (insider trades) sold 58,820 shares of HZNP on 08/22/2019 at an average price of $28 a share. Continue reading...
A rigorous evaluation of the state of care for thyroid eye disease (TED) published in the American Journal of Ophthalmology (AJO) highlights the lack of current therapies to adequately treat the disease. The invited ‘Perspective’ discusses the potential for Horizon’s investigational medicine teprotumumab to change the treatment paradigm. The Biologics License Application (BLA) for teprotumumab is currently being reviewed by the U.S. Food and Drug Administration (FDA) and if approved, teprotumumab could be the first FDA-approved medicine for active TED.
Horizon Therapeutics plc today announced that the company will participate in the following conference in September:
Horizon Therapeutics PLC (NASDAQ: HZNP ), an actively traded small-cap biotech, is poised for further upside in the near-term on its product strength, according to BMO Capital Markets. The Analyst Gary ...
Horizon Therapeutics plc (HZNP) today announced the launch of RAREisCommunity.com, a go-to resource for the more than 350 million people around the world living with rare disease. This website is the latest expansion of Horizon’s #RAREis™ program, which aims to elevate the voices, faces and experiences of the rare disease community. “One common theme that has arisen from our conversations with families and advocates in the rare disease community is the need to bring together resources and advice to help those living with rare diseases and their caregivers navigate through the challenges of life’s transitions,” said Ann Marie Bingo, associate director, patient advocacy, Horizon.
Canada's patented drug price regulator, set to gain new powers next year, may be "more forgiving" in setting price caps for drugs that treat rare diseases, the agency's executive director told Reuters, as some advocates warned the country's pricing reforms would hurt patients. The Canadian government announced final regulations meant to cut drug spending on Friday. The reforms expand the Patented Medicine Prices Review Board's (PMPRB) powers, and among other things give it the ability to consider the cost-effectiveness of medications.
EVP, Corporate Affairs, CCO of Horizon Therapeutics Plc (30-Year Financial, Insider Trades) Geoffrey M. Continue reading...
Horizon Therapeutics stock popped Wednesday after its gout treatment, Krystexxa, drove a beat and raise in the second quarter. Adjusted Horizon earnings also came in better than expected.
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 36.84% and 7.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million --
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors are always looking for growth in small-cap stocks like Horizon Therapeutics Public Limited Company...